Blog

Indication
BOSULIF (bosutinib) is a prescription medicine used for the treatment of adult patients with:
Newly-diagnosed chronic phase Ph+ chronic myelogenous leukemia (CML). This indication is approved under accelerated approval based on molecular and cytogenetic response rates. Continued approval for this indication may be contingent upon verification and confirmation of clinical benefit in an ongoing long-term follow up trial.
Chronic, accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy.
SideEffects
The common side effects of Bosulif 100mg for those patients who are newly diagnosed include: diarrhea, nausea, low platelet counts, rash, stomach pain, and changes in liver function tests.
The common side effects of Bosulif 100mg for those patients who no longer benefit from or did not tolerate other treatment include: diarrhea, nausea, stomach pain, rash, low platelet counts, vomiting, low red blood cell counts, tiredness, fever, cough, headache, changes in liver function tests, and swelling.
Mechanism Of Action
Bosutinib is a type of drug called a protein tyrosine kinase inhibitor (TKI). Tyrosine kinases are proteins that act as chemical messengers to stimulate cancer cells to grow. Bosutinib blocks (inhibits) a protein made by CML cells that have the Philadelphia chromosome. Blocking this protein stops the leukaemia cells growing.